Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive
  • Piperazines
  • Pyrimidines

abstract

  • Imatinib induced high rates of cytogenetic and hematologic responses in patients with chronic-phase CML in whom previous interferon therapy had failed.

publication date

  • February 28, 2002

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1056/NEJMoa011573

PubMed ID

  • 11870241

Additional Document Info

start page

  • 645

end page

  • 52

volume

  • 346

number

  • 9